NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

November 10, 2005 11:27 ET

Medical Publication Highlights Positive Advances in Clinical Studies of Preventive Effects of Statin Drugs in Alzheimer's Disease

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Nov 10, 2005) -

Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

The potential use of statins to treat Alzheimer's disease (AD) is featured in the current issue of Current Opinions in Lipidology (2005;16: 619-623). According to the new article, recent randomized controlled trials give hope for the clinical use of statins in AD patients. In particular, the data suggest that statins may slow cognitive decline in mild to moderate AD.

The article's authors were T. Miida, A. Takahashi, N. Tanabe, and T. Ikeushi, from Nigata University in Japan. The article states that "two randomized controlled trials have suggested that statins slow cognitive decline in mild to moderate Alzheimer's disease", and "large-scale randomized controlled trials of simvastatin and atorvastatin for mild to moderate Alzheimer's disease are underway, which may provide more conclusive results than earlier studies."

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    Web site: www.nymox.com